| View |
|
DRP-1721-03
|
Atorvastatin
|
Gostat 10
|
10 mg
|
Film-Coated Tablet
|
Antihyperlipidemic
|
Umedica Laboratories Pvt. Ltd.
|
India
|
Renewal
|
31 May 2024
|
25 August 2029
|
| View |
|
DRP-2223-05
|
Ampicillin (as sodium)
|
Amzellin-250
|
250 mg / vial
|
Powder for Injection (IV/IM)
|
Antibacterial (Penicillin)
|
Inject Care Parenterals Pvt. Ltd
|
India
|
CLIDP Conversion
|
28 March 2024
|
03 June 2025
|
| View |
|
DRP-236-14
|
Multivitamins + Iron
|
Iroferron
|
(see reverse for formulation)
|
Capsule
|
Hematinic
|
Lloyd Laboratories, Inc.
|
Philippines
|
CLIDP Conversion
|
17 March 2024
|
19 November 2025
|
| View |
|
DRP-13801-01
|
Sugammadex (as sodium)
|
Reverse
|
100 mg/mL
|
Solution for Injection (IV)
|
Antidote
|
Aspiro Pharma Limited
|
India
|
CLIDP Conversion
|
31 July 2023
|
27 April 2028
|
| View |
|
DRP-3010-02
|
Enalapril Maleate
|
Normbeat 5
|
5 mg
|
Tablet
|
Angiotensin Converting Enzyme (ACE) Inhibitor
|
XL Laboratories Pvt. Ltd.
|
India
|
CLIDP Conversion
|
25 March 2024
|
10 December 2029
|
| View |
|
DRP-3123-05
|
Atorvastatin (as Calcium)
|
Atorschwartz 10
|
10 mg
|
Film-Coated Tablet
|
Lipid Modifying Agent (HMG CoA Reductase Inhibitor)
|
Stallion Laboratories Pvt. Ltd.
|
India
|
CLIDP Conversion
|
29 March 2024
|
12 July 2029
|
| View |
|
DRP-3126-07
|
Clopidogrel (as bisulfate)
|
None
|
75 mg
|
Film-Coated Tablet
|
Antithrombotic
|
Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)
|
India
|
CLIDP Conversion
|
21 March 2024
|
14 July 2029
|
| View |
|
DRP-316-04
|
Amoxicillin (as Trihydrate)
|
Limoxil
|
500 mg
|
Capsule
|
Antibacterial (Penicillin)
|
Flamingo Pharmaceuticals Ltd
|
India
|
Automatic Renewal
|
19 March 2024
|
10 March 2029
|
| View |
|
DRP-3168-01
|
Clopidogrel Bisulfate
|
Plogrel
|
75 mg
|
Film-Coated Tablet
|
Antithrombotic
|
Ajanta Pharma Limited
|
India
|
Automatic Renewal
|
27 March 2024
|
16 July 2029
|
| View |
|
DRP-3205-01
|
Co-Amoxiclav
|
Orapen Inj
|
1 g/ 200 mg
|
Powder for Injection (I.V.)
|
Antibacterial (Penicillin-Beta-Lactamase Inhibitor Combination)
|
Inject Care Parenterals Pvt. Ltd.
|
India
|
CLIDP Conversion
|
29 March 2024
|
23 August 2026
|
| View |
|
DRP-3322-06
|
Azithromycin (as Dihydrate)
|
Altozith
|
200 mg/5 mL
|
Powder for Suspension
|
Antibacterial (Macrolide)
|
Stallion Laboratories Pvt. Ltd.
|
India
|
CLIDP Conversion
|
25 March 2024
|
08 July 2029
|
| View |
|
DRP-3322-07
|
Azithromycin (as Dihydrate)
|
Phartobac
|
200 mg/5 mL
|
Powder for Suspension
|
Antibacterial (Macrolide)
|
Stallion Laboratories Pvt. Ltd
|
India
|
Automatic Renewal
|
26 March 2024
|
08 July 2029
|
| View |
|
DRP-4444-02
|
Guaifenesin + Phenylpropanolamine Hydrochloride + Chlorphenamine maleate
|
Conzend
|
50mg/6.25mg/1mg per 5mL
|
Syrup
|
Expectorant/ Decongestant/ Antihistamine
|
Lloyd Laboratories, Inc.
|
Philippines
|
CLIDP Conversion
|
24 March 2024
|
06 June 2025
|
| View |
|
DRP-4515-10
|
Cefuroxime (as sodium)
|
Cefupen 750
|
750 mg
|
Powder for Injection (I.M./I.V.)
|
Antibacterial (Cephalosporin)
|
Zazen Pharma Pvt. Ltd
|
India
|
CLIDP Conversion
|
10 March 2024
|
18 July 2028
|
| View |
|
DRP-4720-02
|
Salmeterol (as xinafoate) + Fluticasone Propionate
|
Zerehaler
|
25 mcg/250 mcg
|
Metered Dose Inhaler (CFC Free)
|
Fixed Dose Combination Inhalation Corticosteroid and Beta-2 Adrenoceptor Agonist
|
Kopran Limited
|
India
|
CLIDP Conversion
|
08 March 2024
|
18 March 2028
|
| View |
|
DRP-4815-07
|
Lactulose
|
Rexulac
|
3.35 g/ 5mL
|
Syrup
|
Osmotic Laxative
|
Opal Laboratories (Pvt.) Limited
|
Pakistan
|
CLIDP Conversion
|
28 March 2024
|
10 February 2027
|
| View |
|
DRP-4838-07
|
Fenofibrate
|
Fenogen
|
200 mg
|
Capsule
|
Lipid Modifying Agent (Fibrates)
|
Azarias Pharmaceutical Laboratories Inc
|
Philippines
|
CLIDP Conversion
|
21 March 2024
|
16 October 2028
|
| View |
|
DRP-4838-08
|
Fenofibrate
|
Fenoceed
|
200 mg
|
Capsule
|
Lipid Modifying Agent (Fibrates)
|
Azarias Pharmaceutical Laboratories Inc
|
Philippines
|
CLIDP Conversion
|
28 March 2024
|
16 October 2028
|
| View |
|
DRP-4839-07
|
Fenofibrate
|
Tripibra
|
160 mg
|
Capsule
|
Lipid Modifying Agent (Fibrates)
|
Azarias Pharmaceutical Laboratories Inc
|
Philippines
|
CLIDP Conversion
|
10 March 2024
|
16 October 2028
|
| View |
|
DRP-4839-09
|
Fenofibrate
|
Fenoceed
|
160 mg
|
Capsule
|
Lipid Modifying Agent (Fibrates)
|
Azarias Pharmaceutical Laboratories Inc.
|
Philippines
|
CLIDP Conversion
|
10 March 2024
|
16 October 2028
|